John Iii Lacy - Net Worth and Insider Trading

John Iii Lacy Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, John Iii Lacy owns 1 companies in total, including Provectus Biopharmaceuticals Inc (PVCT) .

Click here to see the complete history of John Iii Lacy’s form 4 insider trades.

Insider Ownership Summary of John Iii Lacy

Ticker Comapny Transaction Date Type of Owner
PVCT Provectus Biopharmaceuticals Inc 2018-04-27 director

John Iii Lacy Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

John Iii Lacy Ownership Network

Ownership Network List of John Iii Lacy

No Data

Ownership Network Relation of John Iii Lacy

Insider Network Chart

John Iii Lacy Owned Company Details

What does Provectus Biopharmaceuticals Inc do?

Who are the key executives at Provectus Biopharmaceuticals Inc?

John Iii Lacy is the director of Provectus Biopharmaceuticals Inc. Other key executives at Provectus Biopharmaceuticals Inc include 10 percent owner Jeffrey Allen Morris , Chief Financial Officer Heather Raines , and See Remarks John R Glass .

Provectus Biopharmaceuticals Inc (PVCT) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Provectus Biopharmaceuticals Inc (PVCT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Provectus Biopharmaceuticals Inc (PVCT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Provectus Biopharmaceuticals Inc (PVCT)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Provectus Biopharmaceuticals Inc Insider Transactions

No Available Data

John Iii Lacy Mailing Address

Above is the net worth, insider trading, and ownership report for John Iii Lacy. You might contact John Iii Lacy via mailing address: 10025 Investment Drive, Suite 250, Knoxville Tn 37932.

Discussions on John Iii Lacy

No discussions yet.